Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Osivax gets €8mm via Series A

Executive Summary

French vaccines developer Osivax announced today that it has secured €8mm ($9mm) in a Series A financing led by Noshaq (formerly Meusinvest), which was joined by Anaxago. The company will use the funds for ongoing development of its lead flu vaccine candidate and to support strategic growth. Osivax raised €2.7mm in seed funding in June 2017.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies